环氧合酶-2及其抑制剂与肺癌耐药的研究进展  

COX-2 and its inhibitors in lung cancer drug resistance

作　　者：韩惠[1] 张卿[1] 

机构地区：[1]内蒙古医科大学附属医院呼吸内科,呼和浩特010010

出　　处：《国际肿瘤学杂志》2015年第3期203-205,共3页Journal of International Oncology

基　　金：国家自然科学基金（30560175）;内蒙古医科大学附属医院重大科研项目（NYFYZD2012001）

摘　　要：环氧合酶-2（COX-2）是环氧合酶的可诱导形式，在非小细胞肺癌尤其是腺癌中过度表达，并参与肺癌耐药性的产生，降低肿瘤细胞对化疗药物的敏感性。COX-2抑制剂有抗肿瘤并预防肿瘤形成的作用，因此，为逆转肺癌的耐药性，提高肺癌患者的生存率并改善其预后，将COX-2抑制剂作为辅助化疗药物并与化疗药物联合的应用成为了肺癌治疗的新方向。COX-2 is the inducible form of cyclooxygenase,which is overexpressed in non-small cell lung cancer,especially in the adenocarcinoma,and is involved in the production of lung cancer drug resistance, reducing the sensitivities of tumor cells to chemotherapy drugs. COX-2 inhibitors have the effects of antitumor and prevention of tumor formation. Therefore,in order to reverse the drug resistance of tumor cells,improve the sur-vival rate and the prognosis of patients with tumor,the application of COX-2 inhibitors as adjuvant chemotherapy and combined with chemotherapy drugs has become a new direction in the treatment of lung cancer.

关 键 词：肺肿瘤 多药耐药 环氧合酶-2抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]